AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38532251 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-message intervention combining cognitive-behavioural therapy (CBT) texts with techniques from cognitive psychology (message framing) and social psychology (growth mindsets).
Number of subjects: 0
Study 38532251 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain message framing
Number of subjects: 0
Study 38532251 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss message framing
Number of subjects: 0
Study 38532251 — intervention group
Group type: EXPERIMENTAL
Intervention: No message framing
Number of subjects: 0
Study 38532251 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth mindsets
Number of subjects: 0
Study 38532251 — intervention group
Group type: EXPERIMENTAL
Intervention: Not having growth mindsets
Number of subjects: 0
Study 38532258 — intervention group
Group type: COMPARATOR
Intervention: Standard VNS
Number of subjects: 29
Study 38532258 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized microburst VNS
Number of subjects: 29
Study 38532380 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated volume of the contralateral normal testis measured by pre-operative ultrasound
Number of subjects: 76
Study 38532380 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated sonographic volume of a normal testis
Number of subjects: 76
Study 38532390 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise program (3-month outpatient intervention)
Number of subjects: 153
Study 38532395 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication for opioid use disorder (MOUD) with buprenorphine/naloxone (bup/nx) and oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 17
Study 38532395 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication for opioid use disorder (MOUD) with buprenorphine/naloxone (bup/nx)
Number of subjects: 17
Study 38532422 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapeziectomy with abductor pollicis longus (APL) arthroplasty and prosthetic replacement with Maïa® prosthesis
Number of subjects: 106
Study 38532434 — intervention group
Group type: EXPERIMENTAL
Intervention: gelofusine with crystalloid
Number of subjects: 30
Study 38532434 — intervention group
Group type: EXPERIMENTAL
Intervention: albumin with crystalloid
Number of subjects: 30
Study 38532434 — intervention group
Group type: EXPERIMENTAL
Intervention: crystalloid and retrograde autologous priming
Number of subjects: 30
Study 38532451 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate- to vigorous-intensity physical activities combined with low-dose PK-guided EHL FVIII prophylaxis for 6 months
Number of subjects: 13
Study 38532458 — intervention group
Group type: EXPERIMENTAL
Intervention: Belumosudil 200 mg once daily
Number of subjects: 30
Study 38532503 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics (amoxicillin 500 mg/clavulanic acid 125 mg) given after delivery
Number of subjects: 442
Study 38532503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 442
Study 38532768 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled imatinib (AV-101)
Number of subjects: 0
Study 38533127 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with one to two doses
Number of subjects: 8767
Study 38533127 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with three or more doses
Number of subjects: 8767
Study 38533127 — intervention group
Group type: EXPERIMENTAL
Intervention: Encountering COVID-19 in 2022
Number of subjects: 8767
Study 38533127 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization in ICU
Number of subjects: 8767
Study 38533127 — intervention group
Group type: COMPARATOR
Intervention: Age, multiple comorbidities, active malignancy at COVID-19 onset, pulmonary symptoms, and hospitalization
Number of subjects: 8767
Study 38533127 — intervention group
Group type: COMPARATOR
Intervention: Overall mortality rate
Number of subjects: 8767
Study 38533127 — intervention group
Group type: COMPARATOR
Intervention: Critical infections
Number of subjects: 8767
Study 38533552 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulotaront (150 mg)
Number of subjects: 31
Study 38533552 — intervention group
Group type: COMPARATOR
Intervention: Previous antipsychotic (PA)
Number of subjects: 31
Study 38533643 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone ester (KE) treatment for 14 days
Number of subjects: 24
Study 38533643 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric comparator
Number of subjects: 24
Study 38533843 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery-competing task intervention
Number of subjects: 0
Study 38533943 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAD-induced PTSD symptoms
Number of subjects: 859
Study 38533943 — intervention group
Group type: COMPARATOR
Intervention: Lifetime probable SCAD-induced PTSD diagnoses
Number of subjects: 859
Study 38533943 — intervention group
Group type: EXPERIMENTAL
Intervention: Past-month PTSD symptom severity
Number of subjects: 859
Study 38533943 — intervention group
Group type: EXPERIMENTAL
Intervention: Past-month SCAD-induced PTSD symptoms
Number of subjects: 859
Study 38533953 — intervention group
Group type: EXPERIMENTAL
Intervention: Externally developed CAD polygenic risk score (PRS)
Number of subjects: 0
Study 38533953 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol PRS
Number of subjects: 0
Study 38533961 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (selective phosphodiesterase-5 inhibition)
Number of subjects: 212
Study 38533961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 38533985 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF inhibitors (TNFi)
Number of subjects: 158
Study 38533985 — intervention group
Group type: COMPARATOR
Intervention: No TNF inhibitors (Control)
Number of subjects: 158
Study 38533983 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 4094
Study 38533983 — intervention group
Group type: COMPARATOR
Intervention: COPD presence
Number of subjects: 4094
Study 38533983 — intervention group
Group type: COMPARATOR
Intervention: Primary composite outcome
Number of subjects: 4094
Study 38534105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac biofeedback
Number of subjects: 481
Study 38534105 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 481
Study 38534105 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 481
Study 38534162 — intervention group
Group type: EXPERIMENTAL
Intervention: adherence-linked
Number of subjects: 329
Study 38534162 — intervention group
Group type: EXPERIMENTAL
Intervention: clinic-linked
Number of subjects: 329
Study 38534162 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 329
Study 38534892 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based learning module
Number of subjects: 34
Study 38534892 — intervention group
Group type: COMPARATOR
Intervention: Self-learning video
Number of subjects: 34
Study 38535011 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) assessment
Number of subjects: 30
Study 38535011 — intervention group
Group type: COMPARATOR
Intervention: Low-dose non-contrast thoracic CT
Number of subjects: 30
Study 38535039 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring platform using a specialized smartphone application
Number of subjects: 0
Study 38535039 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up approaches (Control)
Number of subjects: 0
Study 38535409 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV20
Number of subjects: 1991
Study 38535409 — intervention group
Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 1991
Study 38536017 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily
Number of subjects: 98
Study 38536017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 38536082 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (120 mg/d) + Relacorilant (escalating doses, RP2D of 150 mg/d)
Number of subjects: 35
Study 38536106 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation Therapy
Number of subjects: 0
Study 38536106 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38536128 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/day nicotinamide
Number of subjects: 1300
Study 38536165 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dimensional Mass Cytometry
Number of subjects: 0
Study 38536165 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38536177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting reduction intervention (10 health coaching contacts, sitting reduction goals, standing desk, fitness tracker)
Number of subjects: 283
Study 38536177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting reduction intervention
Number of subjects: 283
Study 38536177 — intervention group
Group type: COMPARATOR
Intervention: Healthy living attention control (10 health coaching contacts to set general healthy living goals)
Number of subjects: 283
Study 38536225 — intervention group
Group type: EXPERIMENTAL
Intervention: Minder mobile app
Number of subjects: 1489
Study 38536225 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 1489
Study 38536227 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable (LAI) HIV antiretroviral therapy (ART)
Number of subjects: 200
Study 38536227 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-oriented tools for comparing LAI ART and daily oral ART options
Number of subjects: 200
Study 38536227 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation outcomes measured through provider interviews, surveys, and service reporting
Number of subjects: 200
Study 38536442 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV-239 (Hecolin) vaccine, 30 µg administered intramuscularly on days 1, 29, and 180
Number of subjects: 30
Study 38536442 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV-239 (Hecolin) vaccine, 30 µg administered intramuscularly
Number of subjects: 30
Study 38536442 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV-239 (Hecolin) vaccine
Number of subjects: 30
Study 38536442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 38536534 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia
Number of subjects: 318
Study 38536534 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 318
Study 38536534 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hyperlactatemia
Number of subjects: 318
Study 38536534 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate levels during ICU stay
Number of subjects: 318
Study 38536534 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in lactate levels from day one to seven in patients with baseline hyperlactatemia
Number of subjects: 318
Study 38536534 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary increase in lactate
Number of subjects: 318
Study 38536545 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane sedation for 48 hours
Number of subjects: 60
Study 38536545 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous sedation (control)
Number of subjects: 60
Study 38536545 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane sedation
Number of subjects: 60
Study 38536592 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-stitch technique
Number of subjects: 414
Study 38536592 — intervention group
Group type: COMPARATOR
Intervention: Long-stitch technique
Number of subjects: 414
Study 38536592 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 414
Study 38536701 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution manometry (HRM) with Milan Score
Number of subjects: 295
Study 38536764 — intervention group
Group type: EXPERIMENTAL
Intervention: Overminus spectacles (-2.50 D for 12 months, -1.25 D for 3 months, and nonoverminus for 3 months)
Number of subjects: 386
Study 38536764 — intervention group
Group type: COMPARATOR
Intervention: Nonoverminus spectacles
Number of subjects: 386
Study 38536764 — intervention group
Group type: EXPERIMENTAL
Intervention: Overminus spectacles
Number of subjects: 386
Study 38536810 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly intravenous infusion of dual bNAbs (VRCO1LS and 10-1074)
Number of subjects: 25
Study 38536852 — intervention group
Group type: EXPERIMENTAL
Intervention: NoObesity app
Number of subjects: 35
Study 38536994 — intervention group
Group type: EXPERIMENTAL
Intervention: intra-mucosal injection of injectable platelet-rich fibrin (i-PRF)
Number of subjects: 10
Study 38536994 — intervention group
Group type: COMPARATOR
Intervention: no treatment (Control)
Number of subjects: 10
Study 38536997 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Directive document
Number of subjects: 120
Study 38537027 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise delivery mode
Number of subjects: 0
Study 38537027 — intervention group
Group type: EXPERIMENTAL
Intervention: Gym-based exercise delivery mode
Number of subjects: 0
Study 38537027 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 0
Study 38537053 — intervention group
Group type: EXPERIMENTAL
Intervention: M1-rTMS with naloxone
Number of subjects: 45
Study 38537053 — intervention group
Group type: COMPARATOR
Intervention: M1-rTMS with saline
Number of subjects: 45
Study 38537053 — intervention group
Group type: COMPARATOR
Intervention: DLPFC-rTMS with saline
Number of subjects: 45
Study 38537053 — intervention group
Group type: EXPERIMENTAL
Intervention: M1-rTMS or DLPFC-rTMS
Number of subjects: 45
Study 38537155 — intervention group
Group type: EXPERIMENTAL
Intervention: Giredestrant (30 mg oral once daily)
Number of subjects: 303
Study 38537155 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice of endocrine monotherapy (PCET)
Number of subjects: 303
Study 38537251 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut-based whole foods/snacks (PNT group)
Number of subjects: 32
Study 38537251 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate, peanut-free snack (CHO group)
Number of subjects: 32
Study 38537255 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted 3.75 μg + AS03/2017 doses with delayed boost interval
Number of subjects: 180
Study 38537255 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of A(H7N9) IIV
Number of subjects: 180
Study 38537255 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted second dose with longer interval
Number of subjects: 180
Study 38537255 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03 adjuvant with second H7N9 IIV dose and extended boost interval to 4 months
Number of subjects: 180
Study 38537270 — intervention group
Group type: COMPARATOR
Intervention: Whey protein (32 g)
Number of subjects: 10
Study 38537270 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant protein blend (32 g)
Number of subjects: 10
Study 38537315 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD1) administered intravenously until end of treatment (12 months), progression, unacceptable toxicity, or death.
Number of subjects: 39
Study 38537483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 60
Study 38537483 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 60
Study 38537615 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorimetric ETCO2 detector
Number of subjects: 50
Study 38537615 — intervention group
Group type: COMPARATOR
Intervention: Control group (without ETCO2 detector)
Number of subjects: 50
Study 38537636 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (L-T4) plus standard HFrEF treatment
Number of subjects: 117
Study 38537636 — intervention group
Group type: COMPARATOR
Intervention: Standard HFrEF therapy alone
Number of subjects: 117
Study 38537676 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesomersen 40 mg
Number of subjects: 308
Study 38537676 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesomersen 80 mg
Number of subjects: 308
Study 38537676 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesomersen 120 mg
Number of subjects: 308
Study 38537676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 38537676 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesomersen (all doses pooled)
Number of subjects: 308
Study 38537676 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesomersen (all doses)
Number of subjects: 308
Study 38537773 — intervention group
Group type: EXPERIMENTAL
Intervention: OH2 oncolytic viral therapy derived from herpes simplex virus 2 (HSV-2)
Number of subjects: 0
Study 38537780 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice daily
Number of subjects: 360
Study 38537780 — intervention group
Group type: COMPARATOR
Intervention: Apixaban 5 mg twice daily
Number of subjects: 360
Study 38537903 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session, self-guided online acceptance-based workshop targeting food cravings
Number of subjects: 74
Study 38537903 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 74
Study 38537919 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 4796
Study 38537919 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 4796
Study 38537918 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 2127
Study 38537918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2127
Study 38538037 — intervention group
Group type: EXPERIMENTAL
Intervention: Active case detection with molecular (ACDm) testing by high volume quantitative PCR (qPCR)
Number of subjects: 600
Study 38538037 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive case detection with molecular testing (PCDm)
Number of subjects: 600
Study 38538037 — intervention group
Group type: COMPARATOR
Intervention: Standard passive case detection (PCD) using rapid diagnostics tests (RDTs)
Number of subjects: 600
Study 38538057 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue intracranial stenting (RIS) + best medical treatment (BMT)
Number of subjects: 346
Study 38538057 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT) alone
Number of subjects: 346
Study 38538093 — intervention group
Group type: EXPERIMENTAL
Intervention: SNK01 in combination with gemcitabine/carboplatin (n=6)
Number of subjects: 12
Study 38538093 — intervention group
Group type: EXPERIMENTAL
Intervention: SNK01 in combination with cetuximab/gemcitabine/carboplatin (n=6)
Number of subjects: 12
Study 38538093 — intervention group
Group type: EXPERIMENTAL
Intervention: SNK01
Number of subjects: 12
Study 38538093 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (SNK01 + chemotherapy/cetuximab)
Number of subjects: 12
Study 38538093 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 12
Study 38538093 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 12
Study 38538160 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir (cohort 1C)
Number of subjects: 55
Study 38538160 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting rilpivirine (cohort 1R)
Number of subjects: 55
Study 38538161 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir or rilpivirine injections
Number of subjects: 55
Study 38538174 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular resistance reserve (MRR)
Number of subjects: 547
Study 38538174 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary microvascular dysfunction (CMD) defined by MRR ≤3.0
Number of subjects: 547
Study 38538200 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated devices (PCDs)
Number of subjects: 259137
Study 38538200 — intervention group
Group type: COMPARATOR
Intervention: Control (no PCDs)
Number of subjects: 259137
Study 38538225 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged continuous theta burst stimulation (pcTBS) targeting the primary motor cortex (M1)
Number of subjects: 42
Study 38538225 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged continuous theta burst stimulation (pcTBS) targeting the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 42
Study 38538559 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma donor-derived cell-free DNA (dd-cfDNA) measured by the Prospera test (Natera Inc)
Number of subjects: 70
Study 38538559 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression in EMBs assessed by Molecular Microscope Diagnostic System
Number of subjects: 70
Study 38538559 — intervention group
Group type: COMPARATOR
Intervention: Comparison with kidney transplant biopsies (Trifecta-Kidney study)
Number of subjects: 70
Study 38538574 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus capecitabine
Number of subjects: 45
Study 38538574 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 45
Study 38538574 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 45
Study 38538820 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 49
Study 38538820 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 49
Study 38538820 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzbromarone
Number of subjects: 49
Study 38538820 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study 38538861 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidative radiotherapy (RT)
Number of subjects: 261
Study 38538861 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunochemotherapy (R-CHOEP) without RT
Number of subjects: 261
Study 38538867 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic vaccine encoding 20 shared neoantigens derived from selected common oncogenic driver mutations, combined with immune checkpoint inhibitors ipilimumab and nivolumab.
Number of subjects: 19
Study 38538867 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic vaccine regimen (ChAd68 and samRNA) combined with immune checkpoint inhibitors.
Number of subjects: 19
Study 38539083 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAF intervention facilitated remotely via the web (N = 200)
Number of subjects: 500